Frontiers in Pharmacology (Aug 2022)

Puerarin inhibits EMT induced by oxaliplatin via targeting carbonic anhydrase XII

  • Xindong Chen,
  • Zhiruo Zhou,
  • Zhiruo Zhou,
  • Zhi Zhang,
  • Chenhao Zhao,
  • Jiayu Li,
  • Jingwen Jiang,
  • Biao Huang,
  • Yuan Qin

DOI
https://doi.org/10.3389/fphar.2022.969422
Journal volume & issue
Vol. 13

Abstract

Read online

Puerarin is a flavonoid molecule that widely exists in various plants. Puerarin has been reported to exhibit anti-tumor effects in various cancers. However, its exact underlying pharmacological mechanism is unclear. This study evaluated the anticancer effect of puerarin combined with oxaliplatin (OXA) in vitro and in vivo. Our results indicated that puerarin can reverse platinum-based anti-cancer drug resistance, and enhance the OXA’s anticancer effects on breast cancer. Furthermore, puerarin can inhibit migration and reverse the epithelial-mesenchymal transition (EMT) induced by low-dose OXA. Further studies showed that the carbonic anhydrase (CA) XII is a potential target of puerarin. In conclusion, puerarin is expected to become an adjuvant chemotherapy drug and potentially become one of the medicated foods for breast cancer patients.

Keywords